Both of these therapies have attracted the attention of the people
"These findings suggest that cascade testing remains markedly underused, and persistent demographic disparities suggest additional factors at play beyond financial access....The findings may guide efforts to address barriers preventing wider uptake of cascade testing and improve cancer prevention efforts, particularly among racial and ethnic minority groups." To view or add a comment, sign in Happy to share our latest publication in JAMA Network Open
653 However, it is crucial to be cautious about potential adverse effects
In September, the New England Journal of Medicine published Wharton's phase-two trial data showing that a once-a-day pill called orforglipron resulted in a weight reduction of at least 10 per cent after 36 weeks in 46 to 75 per cent of participants
A CDC sharps disposal guidance reference card should be provided to families at the start of therapy
En el ensayo SURMOUNT-1, realizado con pacientes con obesidad o sobrepeso sin diabetes, los participantes tratados con la dosis ms alta de Mounjaro lograron una prdida de peso media del 22,5 % del peso corporal inicial, lo que equivale a ms de 23 kg en muchos casos
